<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653181</url>
  </required_header>
  <id_info>
    <org_study_id>SKoskensalo</org_study_id>
    <nct_id>NCT04653181</nct_id>
  </id_info>
  <brief_title>Preoperative i.v. Iron Substitution in Patients With Colon Cancer</brief_title>
  <acronym>PREFECO</acronym>
  <official_title>Preoperative i.v. Iron Substitution in Patients With Colon Carcinoma and Iron-deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 70% of colon cancer patients are anemic. Preoperative anemia in patients with&#xD;
      colorectal cancer is associated with both impaired disease-free survival and overall&#xD;
      survival. The purpose of this study is to compare the effects of preoperative iv iron&#xD;
      substitution on postoperative recovery in preoperatively anemic (male Hb &lt;130, female Hb&#xD;
      &lt;120) and iron deficient colon cancer patients in a prospective setup. As a primary outcome,&#xD;
      the effect of iv-iron substitution on postoperative complications is investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized preoperative iron substitution for patient with iron deficient anemia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>At study, difference between arms will be evaluated: Complications are analysed using Clavien-Dindo classification https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360123/bin/3TT1.jpg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for red blood cell transfusion</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Participants in need for red blood cells transfusion per arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">514</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Iron arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of patients get i.v. iron preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-iron arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Half of patients are treated without i.v. iron substitution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Iron-arm treated with Ferric carboxymaltose, non-iron arm without</description>
    <arm_group_label>Iron arm</arm_group_label>
    <other_name>Ferinject (intravenous iron )</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Dg: Colon ca&#xD;
&#xD;
          -  The planned measure: the colon resection&#xD;
&#xD;
          -  Men: Hb &lt;130, women: Hb &lt;120 and iron deficiency (elevated TfR, low TrFesat or low&#xD;
             ferritin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hyperreactivity for Ferinject&#xD;
&#xD;
          -  haemochromatosis&#xD;
&#xD;
          -  refusal for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selja K Koskensalo, Md, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abdominal centre, HUCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suvi K Rasilainen, Md, PhD</last_name>
    <phone>+35894711</phone>
    <phone_ext>+358504271748</phone_ext>
    <email>suvi.rasilainen@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jorvi Hospital</name>
      <address>
        <city>Espoo</city>
        <state>HUS</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suvi K Rasilainen, Md, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Zhen L, Zhe S, Zhenning W, Zhifeng M, Zhidong L, Xiaoxia L, Jianguang Y, Huimian X. Iron-deficiency anemia: a predictor of diminished disease-free survival of T3N0M0 stage colon cancer. J Surg Oncol. 2012 Mar 15;105(4):371-5. doi: 10.1002/jso.22032. Epub 2011 Jul 14.</citation>
    <PMID>21761412</PMID>
  </reference>
  <reference>
    <citation>Calvet X, Gené E, ÀngelRuíz M, Figuerola A, Villoria A, Cucala M, Mearin F, Delgado S, Calleja JL. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol Health Care. 2016;24(1):111-20. doi: 10.3233/THC-151074.</citation>
    <PMID>26409561</PMID>
  </reference>
  <reference>
    <citation>Calleja JL, Delgado S, del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis. 2016 Mar;31(3):543-51. doi: 10.1007/s00384-015-2461-x. Epub 2015 Dec 22.</citation>
    <PMID>26694926</PMID>
  </reference>
  <reference>
    <citation>Ristescu I, Pintilie G, Filip D, Jitca M, Fecheta R, Florescu I, Scripcariu V, Filipescu D, Grigoraş I. Perioperative Anemia and Transfusion in Colorectal Cancer Patients. Chirurgia (Bucur). 2019 Mar-Apr;114(2):234-242. doi: 10.21614/chirurgia.114.2.234.</citation>
    <PMID>31060656</PMID>
  </reference>
  <reference>
    <citation>Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL, Napolitano LM. Preoperative anemia in colon cancer: assessment of risk factors. Am Surg. 2002 Jun;68(6):582-7.</citation>
    <PMID>12079143</PMID>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Selja Koskensalo</investigator_full_name>
    <investigator_title>Consultant, abdominal surgeon,Md, PhD</investigator_title>
  </responsible_party>
  <keyword>postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

